Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + JS004 + docetaxel for previously treated advanced non-squamous NSCLC
ChiCTR2400092747Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, tifcemalimab and docetaxel in Non-small cell lung cancer (NS-NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
toripalimabtifcemalimabdocetaxel
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR2400092747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092747.